Trial Profile
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2015
Price :
$35
*
At a glance
- Drugs Opicapone (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Bial
- 27 Jun 2014 New trial record